Form 4: Rhythm Pharmaceuticals Executive Pamela Cramer Reports Stock Option Exercise and Sale

Pamela Cramer, Chief Human Resources Officer of Rhythm Pharmaceuticals, exercised stock options and sold shares under a pre-arranged Rule 10b5-1 trading plan.

Summary

• On April 29, 2025, Pamela Cramer, the Chief Human Resources Officer of Rhythm Pharmaceuticals, exercised stock options to acquire 7,031 shares of common stock at a price of $6.80 per share.
• Simultaneously, Ms. Cramer sold 7,031 shares of common stock at a weighted average price of $65.0922 per share, with individual sales prices ranging from $65 to $65.42.
• These transactions were executed under a Rule 10b5-1 trading plan adopted on December 16, 2024.
• Following these transactions, Ms. Cramer directly owns 19,209 shares of Rhythm Pharmaceuticals common stock and 35,159 stock options.

Sentiment

Score: 5

Explanation: The document is a routine disclosure of stock transactions by a company executive. It doesn't inherently convey positive or negative sentiment, but rather provides factual information about the transactions.

Industry Context

Form 4 filings are standard disclosures required by the SEC when company insiders, like officers and directors, trade in their company's stock. This filing indicates that Pamela Cramer, as Chief Human Resources Officer, exercised stock options and sold a portion of the acquired shares. Such transactions are common and often part of executive compensation packages and pre-planned trading strategies.

Comparison to Industry Standards

• Executive stock option exercises and sales are a common practice across publicly traded companies.
• Rule 10b5-1 trading plans are frequently used by executives to avoid accusations of insider trading, allowing them to sell shares at predetermined times and prices.
• The reported weighted average sale price of $65.0922 per share can be compared to the trading price of RYTM on April 29, 2025, to assess the transaction's value relative to market conditions.

Stakeholder Impact

• The transaction may have a minor impact on shareholders as it involves the sale of shares by a company executive.
• The disclosure provides transparency to stakeholders regarding insider trading activities.

Key Dates

Keywords

Form 4, Rhythm Pharmaceuticals, RYTM, Pamela Cramer, Stock Options, Rule 10b5-1, Executive Compensation, Insider Trading